# Lymphatica Medtech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lymphatica-medtech

- Industry: Medical Devices & Equipment
- Headquarters: Lausanne, Switzerland
- Website: www.lymphaticamedtech.com
- Total disclosed funding: $20M
- Latest round: Series B (Oct 8, 2024)
- Investors on record: 9

## About

Lymphatica Medtech SA, based in Switzerland, develops innovative medical devices to improve lymphatic health and facilitate drainage, particularly for conditions like lymphedema and chronic venous insufficiency.Founded in 2017 and headquartered in Lausanne, Switzerland, Lymphatica Medtech SA focuses on developing advanced medical devices for lymphatic health. The company has successfully completed three investment deals, with the latest being a Series B funding round in October 2024, raising EUR 17.9 million. The founders, Marco Pisano and Valentina Triacca, have a history of entrepreneurship, with Pisano serving as the current CEO.Lymphatica Medtech specializes in innovative medical devices designed to enhance lymphatic health and facilitate drainage. Their primary products are advanced systems for clinical and home use, addressing lymphedema and chronic venous insufficiency. Utilizing pneumatic compression technology, these devices promote fluid movement within the lymphatic system, alleviating swelling and discomfort. The company caters to healthcare facilities, rehabilitation centers, and individual patients seeking to improve their lymphatic function, with a market presence in North America and Europe.Lymphatica Medtech generates revenue through direct sales and partnerships with healthcare providers and distributors. Their business model is primarily B2B, where medical institutions purchase devices for patient treatment, including bulk orders and tailored pricing plans. The company’s products are marketed under distinct branding, ensuring marketplace recognition, while their competitive pricing strategy makes them accessible to both institutional clients and individual consumers seeking home-use devices. Revenue is also supported by ongoing training and support services for healthcare professionals to optimize product use in clinical settings.In October 2024, Lymphatica Medtech SA raised EUR 17.9 million in Series B funding, co-led by Panakes Partners, Techwald Holding, and CDP Venture Capital, among others. This funding will be used to support expansion plans and manage manufacturing and clinical operations. Lymphatica aims to design and launch new products targeting the growing demand for lymphatic health solutions and plans to expand into additional European and North American markets by 2025.

## Funding rounds

- Series B, Oct 8, 2024, $20M — CDP Venture Capital, High-Tech Gruenderfonds, Club Degli Investitori, Zürcher Kantonalbank Asset Management, Panakes Partners, Techwald Holding, Occident Group
- Series A, Dec 3, 2020 — High-Tech Gruenderfonds, EIT Health e.V., LIVEventures

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A, Series B
- EIT Health e.V. — Series A
- LIVEventures (https://capitalatlas.ai/funds/liveventures) — Series A
- CDP Venture Capital (https://capitalatlas.ai/funds/cdp-venture-capital) — Series B
- Club Degli Investitori (https://capitalatlas.ai/funds/club-degli-investitori) — Series B
- Zürcher Kantonalbank Asset Management — Series B
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series B
- Techwald Holding (https://capitalatlas.ai/funds/techwald-holding) — Series B
- Occident Group — Series B